Natco launches generic to treat hepatitis C in Nepal: Natco Pharma announced today that it has launched Velpanat, the first generic version of Gilead's Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination - a single tablet regimen to treat adults with chronic hepatitis C infection - in Nepal.

This launch follows the non-exclusive licensing agreement Natco signed with Gilead to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries. The stock is up 1.08% as of noon today. Natco has seen a strong recent quarter on the back of gTamiflu sales, and numbers will be up next quarter as well since December-March is typically flu season.